Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AOTI, Inc. ( (GB:AOTI) ) just unveiled an announcement.
AOTI, Inc. reported strong financial results for 2024, with a 32.9% increase in revenue driven by growth across all business segments. The company expanded its Medicaid coverage to nine states and secured a five-year extension of its Veterans Administration contract. AOTI also received FDA clearance for its NEXA™ NPWT System for home care use and began a clinical trial for its TWO2® Therapy. The company’s IPO on AIM raised $19.9 million, enhancing its market rollout and reducing debt. AOTI anticipates continued growth, supported by its leadership in advanced wound care and strategic investments in market access.
More about AOTI, Inc.
AOTI, Inc., founded in 2006, operates in the medical technology industry, focusing on the durable healing of wounds and prevention of amputations. The company is known for its patented non-invasive Topical Wound Oxygen (TWO2®) Therapy, which has shown significant reductions in hospitalizations and amputations for diabetic foot ulcers. AOTI’s products are globally recognized, receiving regulatory clearance in multiple regions, and aim to reduce healthcare costs while improving patient quality of life.
YTD Price Performance: -25.68%
Average Trading Volume: 32,899
Technical Sentiment Signal: Strong Buy
Current Market Cap: £87.75M
For an in-depth examination of AOTI stock, go to TipRanks’ Stock Analysis page.